Theriva Biologics
TOVX
30 hedge funds and large institutions have $2.52M invested in Theriva Biologics in 2022 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 9 increasing their positions, 6 reducing their positions, and 5 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 6
0% more ownership
Funds ownership: 0.03% → 0.03% (+0%)
6% less funds holding
Funds holding: 32 → 30 (-2)
21% less capital invested
Capital invested by funds: $3.18M → $2.52M (-$656K)
40% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Truist Financial
Charlotte,
North Carolina
|
+$275K |
| 2 |
Charles Schwab
San Francisco,
California
|
+$31.1K |
| 3 |
Renaissance Technologies
New York
|
+$25.5K |
| 4 |
William Blair & Company
Chicago,
Illinois
|
+$10.5K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$8.64K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
-$87K |
| 2 |
Jane Street
New York
|
-$80K |
| 3 |
Millennium Management
New York
|
-$38K |
| 4 |
HF
HRT Financial
New York
|
-$29K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$17.3K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
26
Jane Street
New York
| – | -$80K | -1,127 | Closed |
|
|
27
Millennium Management
New York
| – | -$38K | -537 | Closed |
|
|
HF
28
HRT Financial
New York
| – | -$29K | -408 | Closed |
|
|
AWM
29
Axxcess Wealth Management
Carlsbad,
California
| – | -$3K | -40 | Closed |
|
30
Rockefeller Capital Management
New York
| – | +$57 | +1 | New |
|
31
Wells Fargo
San Francisco,
California
| – | +$57 | +1 | +33% |
|
32
Fidelity Investments
Boston,
Massachusetts
| – | +$172 | +3 | +300% |
|
TOVX Hedge Fund Activity: Q2 2022 in Review
30 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Theriva Biologics (TOVX) for Q2 2022, worth a combined $2.52M — down 21% from $3.18M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of TOVX and 3 opened new positions — a net loss of 2 holders — while 6 trimmed existing stakes and 9 added.
The largest buyer was Truist Financial, opening a new position worth an estimated $275K. The largest seller was Virtu Financial, exiting entirely with an estimated $87K sold.
- 30 institutional investors held Theriva Biologics (TOVX) as of Q2 2022, down from 32 in Q1 2022.
- Funds reported $2.52M of Theriva Biologics stock for Q2 2022, down 21% quarter-over-quarter.
- 3 funds opened new Theriva Biologics positions in Q2 2022 and 5 closed out, a net change of -2 holders.
- The largest Theriva Biologics buyer in Q2 2022 was Truist Financial, an estimated $275K added.
- The largest Theriva Biologics seller in Q2 2022 was Virtu Financial, an estimated $87K sold.
Based on aggregated 13F filings for Q2 2022.